Morgan Stanley maintains Monopar Therapeutics at Overweight, raises price target to $133 from $130
Morgan Stanley kept Monopar Therapeutics at Overweight, raising its price target to $133 from $130, suggesting an 84.7% upside from the Nov 13 close of $72.
